- Home
- TRNR vs TOVX Comparison
TRNR vs TOVX Comparison
Compare TRNR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- TOVX
- Stock Information
- Founded
- TRNR 2017
- TOVX 2001
- Country
- TRNR United States
- TOVX United States
- Employees
- TRNR N/A
- TOVX N/A
- Industry
- TRNR Consumer Electronics/Appliances
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- TOVX Health Care
- Exchange
- TRNR Nasdaq
- TOVX Nasdaq
- Market Cap
- TRNR 3.9M
- TOVX 4.7M
- IPO Year
- TRNR 2023
- TOVX 2006
- Fundamental
- Price
- TRNR $1.33
- TOVX $1.11
- Analyst Decision
- TRNR
- TOVX Strong Buy
- Analyst Count
- TRNR 0
- TOVX 1
- Target Price
- TRNR N/A
- TOVX $6.00
- AVG Volume (30 Days)
- TRNR 36.5M
- TOVX 45.2K
- Earning Date
- TRNR 03-31-2025
- TOVX 05-06-2025
- Dividend Yield
- TRNR N/A
- TOVX N/A
- EPS Growth
- TRNR N/A
- TOVX N/A
- EPS
- TRNR N/A
- TOVX N/A
- Revenue
- TRNR $3,180,000.00
- TOVX N/A
- Revenue This Year
- TRNR $1,543.45
- TOVX N/A
- Revenue Next Year
- TRNR $54.84
- TOVX N/A
- P/E Ratio
- TRNR N/A
- TOVX N/A
- Revenue Growth
- TRNR 226.82
- TOVX N/A
- 52 Week Low
- TRNR $0.86
- TOVX $1.06
- 52 Week High
- TRNR $1,640.00
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- TRNR 41.14
- TOVX 34.52
- Support Level
- TRNR $1.33
- TOVX $1.26
- Resistance Level
- TRNR $1.68
- TOVX $1.37
- Average True Range (ATR)
- TRNR 0.67
- TOVX 0.11
- MACD
- TRNR -0.00
- TOVX -0.03
- Stochastic Oscillator
- TRNR 15.30
- TOVX 14.04
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.